Lithuania: Difference between revisions

From Beacon
Line 52: Line 52:


=== [[hasPatientAssociation::Patient_Associations:_Patients_Communities_(Lithuania)|Patient Associations: Patients Communities]] ===
=== [[hasPatientAssociation::Patient_Associations:_Patients_Communities_(Lithuania)|Patient Associations: Patients Communities]] ===
'''Sponsor, manager or home institution:''' Various institutions.
'''Primary purpose:''' To provide support, information, advocacy, and a sense of community for individuals affected by cancer, aiming to improve their quality of life and promote awareness, research, and better care.
'''Access to information:''' Information [https://www.nvi.lt/pacientu-bendrijos/].


=== [[hasPatientGuides::Compilation:_ESMO_Patient_Guides_(Lithuania)|Compilation: ESMO Patient Guides]] ===
=== [[hasPatientGuides::Compilation:_ESMO_Patient_Guides_(Lithuania)|Compilation: ESMO Patient Guides]] ===

Revision as of 18:06, 20 May 2024

Go back to Cancer Centers list.

Cancer Centers

Healthcare System

Administrative or Claims Data

Registries

Clinical Practices Guidelines

Latest Policymaking Initiatives

Cancer-related Patient Associations and Resources

Patient Associations: Patients Communities

Compilation: ESMO Patient Guides

Sponsor, manager or home institution: European Society for Medical Oncology.

Primary purpose: To translate complex medical language into understandable information for patients.

Available guides: Surviving Cancer; AML; Follicular lymphoma; CML; Glioblastoma; Bone Sarcoma; Soft Tissue Sarcomas; Colorectal Cancer; Breast Cancer; Squamous Cell Carcinoma of the Head and Neck Region; Cancer of the Uterus (Endometrium).

Type of information: Information on each guide varies for each cancer type. Generally, guides provide definitions, explanations of causes, diagnosis, treatment, treatment options, care after treatment, among others.

Access to information: List of guides [1].

Quality of Life and Palliative Care Research

List of Articles: Quality of Life [2] and Palliative Care [3].